IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve

IDXX Q2 Beat Reflects Recurring Diagnostics Strength

Second-quarter earnings reached $4.27 per share, up 18% year over year and 8.1% above the Zacks Consensus Estimate. Revenues rose 10% to $1.22 billion and exceeded the consensus mark by 1.3%.

Companion Animal Group Diagnostics recurring revenues increased 10% organically. Higher volumes, greater testing utilization and adoption of newer offerings helped sustain growth despite softer U.S. veterinary visits.

IDXX Raises EPS View After Stronger Quarterly Profit

IDEXX raised its 2026 earnings outlook to $14.69-$14.94 per share from $14.45-$14.90. The revision followed a quarter in which operating profit increased 14% to $425.6 million.

Per the Zacks Consensus Estimate, IDXX’s earnings for 2026 is pegged at $14.81. 

Image Source: Zacks Investment Research

Operating margin expanded 140 basis points to 35%, while gross margin also improved 140 basis points to 64%. Recurring revenue volume gains, operational productivity and net price realization helped convert revenue growth into stronger profitability.

IDXX Guidance Balances Growth With Currency Pressure

The company updated 2026 revenue guidance to $4.70-$4.75 billion from $4.68-$4.76 billion. It now expects reported revenue growth of 9.1-10.3% and organic growth of 8.5-9.7%.

The midpoint rose $5 million despite a projected $15-million headwind from updated foreign-exchange assumptions. Currency can therefore weigh on reported growth without changing the underlying demand picture, and management expects about a 70-basis-point currency drag on third-quarter reported revenue growth.

IDXX Innovation Supports the Updated Outlook

VetLab consumables revenues increased 13.6% organically, supported by higher utilization, recent launches, net new customers and an 11% increase in the global premium instrument installed base. The inVue Dx installed base topped 9,000 instruments after 1,602 second-quarter placements, while Cancer Dx surpassed 10,000 ordering clinics globally.

International Companion Animal Group Diagnostics recurring revenues advanced nearly 12% organically. IDEXX plans to expand its commercial footprint in four international countries during the remainder of 2026, adding another avenue for customer and product adoption.

Abbott Laboratories ABT provides a relevant diagnostics comparison through its core laboratory, molecular and point-of-care platforms. Labcorp Holdings Inc. LH offers another benchmark through its broad laboratory-services and diagnostics capabilities.

IDXX Still Contends With Softer Veterinary Traffic

U.S. same-store clinical visits declined an estimated 1.3% in the second quarter, while wellness visits fell 3.4%. Management assumes an approximately 1.5% decline in U.S. clinical visits during the second half of 2026.

Higher diagnostic intensity, broader testing menus and growth among pets aged five years and older are helping offset weaker traffic. Still, prolonged wellness softness could pressure reference laboratory demand because that testing carries greater exposure to wellness activity.

Based on short-term price targets offered by 13 analysts, the average price target for IDEXX comes to $728.31. The average price target represents an increase of 29.55% from the last closing price. 

Image Source: Zacks Investment Research

IDXX Ratings Keep the Earnings Momentum in Check

The raised outlook and margin expansion support the case for durable operating momentum, but softer veterinary traffic, currency volatility and valuation keep the setup balanced. IDXX trades at 34.7X forward 12-month earnings, above the Zacks sub-industry's 26.1X multiple.

The stock currently carries a Zacks Rank #3 (Hold). Its Growth Score of A and Momentum Score of B are favorable, while the Value Score of D points to valuation as a constraint. The VGM Score of B reflects a generally positive blend of growth, momentum and value characteristics, but the #3 Rank supports a measured rather than aggressive stance. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research